Objective:

To present early postapproval experiences and outcomes associated with Encelto in the treatment of macular telangiectasia type 2 (MacTel).

Approach:

Key Findings:

• Pooled data from three randomized, sham-controlled studies demonstrated a 36% reduction in photoreceptor loss over two years.
• Treatment resulted in a 68% reduction in the loss of monocular reading speed and a 35% reduction in retinal sensitivity loss compared to controls.
• Real-world safety findings were consistent with clinical trials, with approximately 20% of patients experiencing mild delayed dark adaptation and miosis.

Interpretation:

Younger patients, those with smaller areas of ellipsoid zone loss, and those without foveal involvement are identified as the strongest responders to Encelto.

Limitations:

• Patient selection remains crucial, with recommendations based on structural evidence, symptoms, and disease progression.

Conclusion:

Encelto appears to address a longstanding treatment gap for patients with MacTel.

Sources:

• Clinical Trials at the Summit
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.